Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


[Identification of T cell epitopes of p210(bcr-abl); antigen and detection of epitope-specific CTLs.].

Zhang J, Wang LH, Gong WJ, Qian YY, Jiang YW, Ji MC.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009 Dec;25(12):1161-3. Chinese.


Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.

Sun JY, Senitzer D, Forman SJ, Chatterjee S, Wong KK Jr.

Cancer Immunol Immunother. 2003 Dec;52(12):761-70. Epub 2003 Oct 17.


Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.

Sun JY, Krouse RS, Forman SJ, Senitzer D, Sniecinski I, Chatterjee S, Wong KK Jr.

Cancer Res. 2002 Jun 1;62(11):3175-83.


[Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].

Zhu XZ, Yu YZ, Fang YM, Liang Y, Lü QH, Xu RZ.

Zhonghua Yi Xue Za Zhi. 2005 Jul 20;85(27):1903-6. Chinese.


Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.

Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet JG, Choppin J.

Eur J Immunol. 1997 Aug;27(8):2066-72.


CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.

Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao S, Kishi K, Kubonishi I, Dan K, Fujita S.

Blood. 1998 Nov 1;92(9):3355-61.


Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.

Tan LC, Mowat AG, Fazou C, Rostron T, Roskell H, Dunbar PR, Tournay C, Romagné F, Peyrat MA, Houssaint E, Bonneville M, Rickinson AB, McMichael AJ, Callan MF.

Arthritis Res. 2000;2(2):154-64. Epub 2000 Feb 7.


BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.

Rusakiewicz S, Madrigal A, Travers P, Dodi AI.

Cancer Immunol Immunother. 2009 Sep;58(9):1449-57. doi: 10.1007/s00262-009-0703-x. Epub 2009 Apr 10.


p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.

van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC.

Blood. 1996 Jun 15;87(12):5213-7.


BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.

Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC, Ossendorp F, Melief CJ.

Leukemia. 2006 Oct;20(10):1738-50. Epub 2006 Aug 24.


Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.

Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA.

Haematologica. 2005 Oct;90(10):1324-32.


Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P.

J Clin Invest. 1998 May 15;101(10):2290-6.


Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.

Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE.

Haematologica. 2005 Oct;90(10):1315-23.


Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, Gostick E, Yamada K, Melenhorst J, Childs R, Hensel N, Douek DC, Barrett AJ.

Blood. 2003 Oct 15;102(8):2892-900. Epub 2003 Jun 26.


A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.

Zorn E, Orsini E, Wu CJ, Stein B, Chillemi A, Canning C, Alyea EP, Soiffer RJ, Ritz J.

Transplantation. 2001 Apr 27;71(8):1131-7.


HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.

Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M, van Biezen JH, Hermans J, Willemze R, Niederwieser D.

Blood. 1999 Jun 1;93(11):3863-5.


Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.

Bertazzoli C, Marchesi E, Passoni L, Barni R, Ravagnani F, Lombardo C, Corneo GM, Pioltelli P, Pogliani E, Gambacorti-Passerini C.

Clin Cancer Res. 2000 May;6(5):1931-5.


Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia.

Zha X, Chen S, Yang L, Li B, Chen Y, Yan X, Li Y.

Hum Immunol. 2011 Oct;72(10):798-804. doi: 10.1016/j.humimm.2011.06.015. Epub 2011 Jul 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk